Optimal Dose and Method of Administration of Intravenous Insulin in the Management of Emergency Hyperkalemia: A Systematic Review

Ziv Harel, Kamel S Kamel, Ziv Harel, Kamel S Kamel

Abstract

Background and objectives: Hyperkalemia is a common electrolyte disorder that can result in fatal cardiac arrhythmias. Despite the importance of insulin as a lifesaving intervention in the treatment of hyperkalemia in an emergency setting, there is no consensus on the dose or the method (bolus or infusion) of its administration. Our aim was to review data in the literature to determine the optimal dose and route of administration of insulin in the management of emergency hyperkalemia.

Design, setting, participants, & measurements: We searched several databases from their date of inception through February 2015 for eligible articles published in any language. We included any study that reported on the use of insulin in the management of hyperkalemia.

Results: We identified eleven studies. In seven studies, 10 units of regular insulin was administered (bolus in five studies, infusion in two studies), in one study 12 units of regular insulin was infused over 30 minutes, and in three studies 20 units of regular insulin was infused over 60 minutes. The majority of included studies were biased. There was no statistically significant difference in mean decrease in serum potassium (K+) concentration at 60 minutes between studies in which insulin was administered as an infusion of 20 units over 60 minutes and studies in which 10 units of insulin was administered as a bolus (0.79±0.25 mmol/L versus 0.78±0.25 mmol/L, P = 0.98) or studies in which 10 units of insulin was administered as an infusion (0.79±0.25 mmol/L versus 0.39±0.09 mmol/L, P = 0.1). Almost one fifth of the study population experienced an episode of hypoglycemia.

Conclusion: The limited data available in the literature shows no statistically significant difference between the different regimens of insulin used to acutely lower serum K+ concentration. Accordingly, 10 units of short acting insulin given intravenously may be used in cases of hyperkalemia. Alternatively, 20 units of short acting insulin may be given as a continuous intravenous infusion over 60 minutes in patients with severe hyperkalemia (i.e., serum K+ concentration > 6.5 mmol/L) and those with marked EKG changes related to hyperkalemia (e.g., prolonged PR interval, wide QRS complex) as an alternative to 10 units of short acting insulin. Because the risk of hypoglycemia is increased with using large insulin doses, sufficient glucose (60 grams with the administration of 20 units of insulin and 50 grams with the administration of 10 units) should be given to prevent hypoglycemia, and plasma glucose should be frequently monitored.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Study selection.
Fig 1. Study selection.

References

    1. Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalemia. The American journal of emergency medicine. 2000;18(6):721–9. Epub 2000/10/24. 10.1053/ajem.2000.7344 .
    1. Kamel KS, Wei C. Controversial issues in the treatment of hyperkalaemia. Nephrology Dialysis Transplantation. 2003;18(11):2215–8. .
    1. Weisberg LS. Management of severe hyperkalemia. Critical Care Medicine. 2008;36(12):3246–51. 10.1097/CCM.0b013e31818f222b. 10.1097/CCM.0b013e31818f222b
    1. Elliott MJ, Ronksley PE, Clase CM, Ahmed SB, Hemmelgarn BR. Management of patients with acute hyperkalemia. CMAJ Canadian Medical Association Journal. 2010;182(15):1631–5. 10.1503/cmaj.100461. 10.1503/cmaj.100461
    1. Sambandam K, Vijayan A. Potassium In: Cooper DH, Krainik AJ, Lubner SJ, Reno HEL, Micek S, editors. The Washington manual of medical therapeutics. 32 ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2007.
    1. Mount DB. Disorders of Potassium Balance In: Taal MW, Chertow GM, Marsden PA, Skorecki K, LYu AS, Brenner BM, editors. Brenner & Rector's the kidney. Philadelphia, PA: Elsevier/Saunders; 2012.
    1. Mount DB. Disorders of Potassium In: Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J, editors. Harrison's Principles of Internal Medicine. 18th ed: McGraw-Hill Professional; 2011.
    1. Mount DB. Treatment and prevention of hyperkalemia in adults.: Wolters Kluwer; 2015 [cited 2015 January 20, 2015.]. Available from: .
    1. Mahoney BA, Smith WA, Lo DS, Tsoi K, Tonelli M, Clase CM. Emergency interventions for hyperkalaemia. The Cochrane database of systematic reviews. 2005;(2):Cd003235 Epub 2005/04/23. 10.1002/14651858.CD003235.pub2 .
    1. Ahee P, Crowe AV. The management of hyperkalaemia in the emergency department. Journal of accident & emergency medicine. 2000;17(3):188–91. Epub 2000/05/20. ; PubMed Central PMCID: PMCPmc1725366.
    1. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama. 2000;283(15):2008–12. Epub 2000/05/02. .
    1. Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney International. 1990;38(5):869–72. .
    1. Sterne JAC HJ, Reeves BC on behalf of the development group for ACROBAT-NRSI,. A Cochrane Risk Of Bias Assessment Tool: for Non-Randomized Studies of Interventions (ACROBAT-NRSI), Version 1.0.0 2014 [cited 2015 October 10]. Available from:
    1. Higgins JPT AD, Sterne JAC (editors),. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 2011. Available from: .
    1. Kim HJ. Combined effect of bicarbonate and insulin with glucose in acute therapy of hyperkalemia in end-stage renal disease patients. Nephron. 1996;72(3):476–82. .
    1. Mushtaq MA, Masood M. Treatment of hyperkalemia with salbutamol and insulin. Pakistan Journal of Medical Sciences. 2006;22(2):176–9. .
    1. Mahajan SK, Mangla M, Kishore K. Comparison of aminophylline and insulin-dextrose infusions in acute therapy of hyperkalemia in end-stage renal disease patients. J Assoc Physicians India. 2001;49:1082–5. .
    1. Allon M. Medical and dialytic management of hyperkalemia in hemodialysis patients. International Journal of Artificial Organs. 1996;19(12):697–9. .
    1. Ngugi NN, McLigeyo SO, Kayima JK. Treatment of hyperkalaemia by altering the transcellular gradient in patients with renal failure: effect of various therapeutic approaches. East African medical journal. 1997;74(8):503–9. .
    1. Blumberg A, Weidmann P, Shaw S, Gnadinger M. Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. American Journal of Medicine. 1988;85(4):507–12. .
    1. Duranay M, Ates K, Erturk S, Duman N, Karatan O, Erbay B, et al. Comparison of aminophylline and insulin infusions in treatment of hyperkalemia in patients with end-stage renal disease [5]. Nephron. 1996;73(1):105 .
    1. Lens XM, Montoliu J, Cases A, Campistol JM, Revert L. Treatment of hyperkalaemia in renal failure: salbutamol v. insulin. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—European Renal Association. 1989;4(3):228–32. PubMed PMID: CN-00260261 UPDATE.
    1. Ljutic D, Rumboldt Z. Should glucose be administered before, with, or after insulin, in the management of hyperkalemia? Renal Failure. 1993;15(1):73–6. .
    1. Chothia MY, Halperin ML, Rensburg MA, Hassan MS, Davids MR. Bolus administration of intravenous glucose in the treatment of hyperkalemia: a randomized controlled trial. Nephron Physiol. 2014;126(1):1–8. Epub 2014/03/01. 10.1159/000358836 .
    1. Allon M, Shanklin N. Effect of bicarbonate administration on plasma potassium in dialysis patients: interactions with insulin and albuterol. American journal of kidney diseases: the official journal of the National Kidney Foundation. 1996;28(4):508–14. PubMed PMID: CN-00131067 UPDATE.
    1. Kamel KS, Schreiber M, Halperin ML. Integration of the response to a dietary potassium load: a paleolithic perspective. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—European Renal Association. 2014;29(5):982–9. 10.1093/ndt/gft499 .
    1. Nguyen TQ, Maalouf NM, Sakhaee K, Moe OW. Comparison of insulin action on glucose versus potassium uptake in humans. Clinical journal of the American Society of Nephrology: CJASN. 2011;6(7):1533–9. 10.2215/CJN.00750111
    1. Ho K. A critically swift response: insulin-stimulated potassium and glucose transport in skeletal muscle. Clinical journal of the American Society of Nephrology: CJASN. 2011;6(7):1513–6. 10.2215/CJN.04540511 .
    1. Ahee P, Crowe AV. The management of hyperkalaemia in the emergency department. J Accid Emerg Med. 2000;17(3):188–91.
    1. Mahoney BA, Smith WAD, Lo DS, Tsoi K, Tonelli M, Clase CM. Emergency interventions for hyperkalaemia. Cochrane Database of Systematic Reviews. 2005;(2):CD003235 .
    1. DeFronzo RA, Felig P, Ferrannini E, Wahren J. Effect of graded doses of insulin on splanchnic and peripheral potassium metabolism in man. Am J Physiol. 1980;238(5):E421–7. Epub 1980/05/01. .
    1. Montague BT, Ouellette JR, Buller GK. Retrospective review of the frequency of ECG changes in hyperkalemia. Clin J Am Soc Nephrol. 2008;3(2):324–30. 10.2215/CJN.04611007. 10.2215/CJN.04611007
    1. Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med. 2013;126(3):264 e9–24. Epub 2013/01/17. 10.1016/j.amjmed.2012.08.016 .
    1. Kamel KS, Schreiber M. Asking the question again: are cation exchange resins effective for the treatment of hyperkalemia? Nephrol Dial Transplant. 2012;27(12):4294–7. Epub 2012/09/20. 10.1093/ndt/gfs293 .

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe